PHILADELPHIA — A multiple
myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple
myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies,
whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.